Transcutaneous Posterior Nerve Stimulation inTreatment of Fecal Incontience

Sponsor
Batterjee Medical College (Other)
Overall Status
Completed
CT.gov ID
NCT04478799
Collaborator
Benha University (Other)
102
1
2
34.4
3

Study Details

Study Description

Brief Summary

Shafik and colleagues were the first to report the use of posterior tibial nerve stimulation (PTNS) for FI, and they documented improved continence after 4 weeks course. Subsequent studies documented percutaneous and transcutaneous PTNS as effective methods for treatment of FI, with a short term reduction in incontinence episode by 50-80 %. Percutaneous PTNS (PPTNS) showed a greater effect than transcutaneous PTNS (TPTNS) and this may be assumed due to the presence of the stimulating electrode very close to the posterior tibial nerve. However, TPTNS is more preferable to percutaneous PTNS because of the concern about the insertion of a needle may result in stimulation that is sufficient to produce a neuromodulatory effect.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcutanous Posterior Tibial Nerve Stimulation
  • Device: Sham Transcutanous Posterior Tibial Nerve Stimulation
N/A

Detailed Description

Treatment of FNRFI is often difficult and requires prolonged therapies with unexpected responses and frequent relapses. The corner-stones in treatment of FNRFI are education, positive motivation, and toilet training. Preparation of children and their parents for a long-lasting treatment is mandatory with the expectation of many ups and downs. The main goal is to have regular bowel movements and normal continence and this can be achieved by teaching the child the importance of regular toilet use and avoid urges.

Many previous studies, reported the short term effect of TPTNS in treatment of FNRFI. However, there are sufficient studies evaluating the long term effect of TPNS and this has motivated the authors to conduct of this study The aim of this study is to evaluate the Long term outcome and quality of life in children with Functional non-retentive fecal incontinence and received Bilateral Transcutaneous posterior tibial nerve stimulation therapy.

Study Design

Study Type:
Interventional
Actual Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The current single-blind randomized controlled study included 102 children with FNRF who were randomly allocated into two groups. Group 1, Bilateral transcutaneous posterior tibial nerve stimulation and group B, Sham TPTNS. Inclusion criteria included those with FI and normal defecation frequency, normal bowel habits and stool consistency. Children younger than 4 years or those who are not cooperative, or those with traumatic sphincter injury, fecal impaction, spinal diseases causing incontinence, anorectal malformation, were excluded from the study.The current single-blind randomized controlled study included 102 children with FNRF who were randomly allocated into two groups. Group 1, Bilateral transcutaneous posterior tibial nerve stimulation and group B, Sham TPTNS. Inclusion criteria included those with FI and normal defecation frequency, normal bowel habits and stool consistency. Children younger than 4 years or those who are not cooperative, or those with traumatic sphincter injury, fecal impaction, spinal diseases causing incontinence, anorectal malformation, were excluded from the study.
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Long Term Outcome of Transcutaneous Posterior Tibial Nerve Stimulation in Treatment of Functional Non-Retentive Fecal Incontinence
Actual Study Start Date :
Sep 1, 2017
Actual Primary Completion Date :
May 1, 2020
Actual Study Completion Date :
Jul 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A (Transcutanous Posterior Tibial Nerve Stimulation)

Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises

Device: Transcutanous Posterior Tibial Nerve Stimulation
children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months

Sham Comparator: Group B (Sham Control)

Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises

Device: Sham Transcutanous Posterior Tibial Nerve Stimulation
Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.

Outcome Measures

Primary Outcome Measures

  1. Number of incontinence episodes [24 months]

    Change in the number of incontinence episodes

  2. Incontinence Score using Vaizey incontinence score [24 months]

    Questionnaire ranging from zero (indicating complete continence) to 24 (indicating total incontinence).

Secondary Outcome Measures

  1. Fecal Incontinence Quality of life Score [24 months]

    Change in quality of life score measured on a scale between 1 and 4, where 1 is very affected and 4 is not affected

  2. Resting pressure (mm hg) [3 months]

    Pressure during relaxation of the anal sphincter

  3. Squeeze pressure (mm hg) [3 months]

    Pressure during contraction of the anal sphincter

  4. First sensation (volume of the balloon by cm water) [3 months]

    First sensation of the stool in the rectum

  5. First Urge (volume of the balloon by cm water) [3 months]

    The patient is trying to hold defecation and he can

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 14 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ranged from (6-14 years) with FNRFI with normal bowel habits

  • Children with normal defecation frequency and normal stool consistency

  • Children with incontinence score ranging from 8-22 according to Vaizey score

Exclusion Criteria:
  • Children who have traumatic sphincter injury.

  • Children who have Fecal impaction

  • Children who have Spinal diseases causing incontinence

  • Children who have Anorectal malformation

  • Children who were not cooperative

Contacts and Locations

Locations

Site City State Country Postal Code
1 Benha University Banhā Al Qalyubia Governorate Egypt 13511

Sponsors and Collaborators

  • Batterjee Medical College
  • Benha University

Investigators

  • Study Director: Mohamed S Kharoub, MD, Faculty of Medicine- Benha University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mohamed A. Abdel Ghafar, Associate Professor, Batterjee Medical College
ClinicalTrials.gov Identifier:
NCT04478799
Other Study ID Numbers:
  • Banha University
First Posted:
Jul 21, 2020
Last Update Posted:
Jul 22, 2020
Last Verified:
Jul 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mohamed A. Abdel Ghafar, Associate Professor, Batterjee Medical College
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 22, 2020